Shield Therapeutics net sales grow in Q2, CEO stands down
Shield Therapeutics
3.30p
11:44 11/03/25
Commercial-stage pharmaceutical company Shield Therapeutics said on Wednesday that total net sales had grown in Q2, driven by "robust" increases in prescriptions and higher net selling prices.
FTSE AIM All-Share
683.06
13:15 11/03/25
Pharmaceuticals & Biotechnology
22,319.41
13:15 11/03/25
Shield Therapeutics said its iron ore replacement therapy, ACCURUFeR, posted quarter-on-quarter sales growth of 69% to $6.9m, while total prescriptions rose 26% to more than 36,400 and average net selling price per prescription increased from $139 to $171.
The AIM-listed group said it had cash and equivalents of $8.1m as of 30 June, excluding the $5.7m in funding it received from its Chinese milestone monetisation announced on 3 July.
Shield Therapeutics also revealed chief executive Greg Madison had stood down from the board in order to pursue other opportunities and will be leaving the company with immediate effect. Non-executive director Anders Lundstrom will take over the job on an interim basis.
As of 0915 BST, Shield Therapeutics shares had surged 42.94% to 2.43p.
Reporting by Iain Gilbert at Sharecast.com